Alternatives to Novo Nordisk

Biopharmaceutical company focused on rare genetic diseases of obesity.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

Global pharmaceutical company focused on developing and manufacturing medicines.

Israeli startup developing non-invasive technology to treat obesity by reversing insulin resistance.

Biotechnology company focused on developing treatments for rare metabolic diseases.

Biopharmaceutical company focused on developing and commercializing innovative treatments for rare neurological disorders.

Clinical-stage biotechnology company developing Antibody Oligonucleotide Conjugates (AOCs) for serious diseases.

Biopharmaceutical company developing transformative therapies for rare metabolic diseases, focusing on hyperinsulinism.

Gene therapy company developing treatments for rare inherited diseases.

Biotech company focused on developing therapies to extend human healthspan and lifespan.

A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.

A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.

Lutris Pharma is a biotechnology company focused on developing novel therapies for rare genetic diseases.

Develops advanced gene editing and cell therapy solutions for rare genetic diseases.

Leveraging the adaptive immune system to diagnose and treat disease.

BioAge Labs is a biotechnology company focused on developing therapies to extend human healthspan and lifespan.

A global oncology company developing and commercializing innovative cancer treatments.

Synthace provides a no-code cloud platform for life sciences R&D, enabling scientists to automate experimentation and insight sharing.

Developing engineered biologics to harness the immune system for disease treatment.

Clinical-stage genetic medicine company developing AAV-mediated treatments for cardiovascular and Alzheimer's diseases.